Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
637 studies found for:    merkel cell carcinoma OR merkel cell cancer OR Neuroendocrine Carcinoma | merkel cell carcinoma OR merkel cell cancer OR Neuroendocrine Carcinoma
Show Display Options
Rank Status Study
21 Recruiting Treatment of Unresecable and/or Metastatic Merkel Cell Carcinoma by Somatostatine Analogues
Condition: Carcinoma, Merkel Cell
Intervention: Drug: Lanreotide
22 Recruiting Everolimus and Temozolomide in Advanced Gastroenteropancreatic Neuroendocrine Carcinoma (G3)
Condition: Neuroendocrine Carcinoma
Intervention: Drug: Everolimus , temozolomide
23 Not yet recruiting Phase II Study to Evaluate the Efficacy and Safety of TLC388 for Differentiated Neuroendocrine Carcinomas Patients
Condition: Neuroendocrine Carcinomas
Intervention: Drug: TLC 388
24 Not yet recruiting Optimization for the Treatment of Advanced Pulmonary Large Cell Neuroendocrine Carcinoma
Condition: Pulmonary Large Cell Neuroendocrine Carcinoma
Interventions: Drug: etoposide plus carboplatin;   Drug: Paclitaxel plus carboplatin
25 Completed
Has Results
Avastin (Bevacizumab) and RAD001 (Everolimus) in Advanced Low or Intermediate Grade Neuroendocrine Carcinoma
Condition: Neuroendocrine Carcinoma
Interventions: Drug: Avastin;   Drug: RAD001
26 Not yet recruiting Assessment of the Efficacy of Bevacizumab in Combination With Folfiri as Second-line Treatment in Patients Suffering From an Advanced Inoperable Poorly Differentiated Neuroendocrine Carcinoma of an Unknown or Gastroentero-pancreatic Primary Cancer
Condition: Neuroendocrine Carcinomas
Interventions: Drug: Folfiri-bevacizumab;   Drug: Folfiri
27 Completed Safety and Efficacy of Atiprimod Treatment for Patients With Low to Intermediate Grade Neuroendocrine Carcinoma
Condition: Neuroendocrine Carcinoma
Intervention: Drug: Atiprimod
28 Completed Paclitaxel, Carboplatin, and Oral Etoposide Followed by Weekly Paclitaxel in High Grade Neuroendocrine Carcinoma
Condition: Neuroendocrine Carcinoma
Interventions: Drug: Paclitaxel;   Drug: Carboplatin;   Drug: Etoposide
29 Completed Extension Study of the Safety and Efficacy of Atiprimod Treatment in Neuroendocrine Carcinoma
Condition: Neuroendocrine Carcinoma
Intervention: Drug: Atiprimod
30 Recruiting A Feasibility Study Of NAB-Paclitaxel In Combination With Carboplatin As First Line Treatment Of Gastrointestinal Neuroendocrine Carcinomas
Condition: Gastrointestinal Neuroendocrine Carcinomas
Interventions: Drug: NAB paclitaxel;   Drug: Carboplatin
31 Recruiting SC-002 in Small Cell Lung Cancer and Large Cell Neuroendocrine Carcinoma
Conditions: Small Cell Lung Cancer;   Large Cell Neuroendocrine Carcinoma
Intervention: Drug: SC-002
32 Completed
Has Results
RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma
Conditions: Neuroendocrine Carcinoma;   Islet Cell Carcinoma
Interventions: Drug: RAD001;   Drug: Octreotide Depot
33 Unknown  Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas
Condition: Well-differentiated Non-pancreatic Neuroendocrine Carcinoma
Interventions: Drug: Axitinib;   Drug: Sandostatin LAR;   Drug: Placebo
34 Active, not recruiting 3-arm Trial to Evaluate Pasireotide LAR/Everolimus Alone/in Combination in Patients With Lung/Thymus NET - LUNA Trial
Condition: Neuroendocrine Carcinoma of the Lung and Thymus
Interventions: Drug: Pasireotide LAR;   Drug: Everolimus;   Drug: Pasireotide LAR + Everolimus
35 Completed Irinotecan in Treating Patients With Advanced Neuroendocrine Tumors
Conditions: Carcinoma of Unknown Primary;   Neuroendocrine Carcinoma;   Neuroendocrine Carcinoma of the Skin
Intervention: Drug: irinotecan hydrochloride
36 Completed BB-10901 in Treating Patients With Relapsed or Refractory Solid Tumors
Conditions: Ovarian Cancer;   Merkel Cell Carcinoma;   SCLC
Intervention: Drug: BB-10901
37 Completed Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma
Conditions: Gastrin-Producing Neuroendocrine Tumor;   Lung Carcinoid Tumor;   Metastatic Digestive System Neuroendocrine Tumor G1;   Pancreatic Glucagonoma;   Pancreatic Insulinoma;   Pancreatic Polypeptide Tumor;   Paraganglioma;   Recurrent Digestive System Neuroendocrine Tumor G1;   Recurrent Merkel Cell Carcinoma;   Recurrent Pancreatic Neuroendocrine Carcinoma;   Regional Digestive System Neuroendocrine Tumor G1;   Somatostatin-Producing Neuroendocrine Tumor;   Stage III Merkel Cell Carcinoma;   Stage IV Merkel Cell Carcinoma;   Thyroid Gland Medullary Carcinoma
Interventions: Biological: Cixutumumab;   Drug: Everolimus;   Other: Laboratory Biomarker Analysis;   Drug: Octreotide Acetate;   Other: Pharmacological Study
38 Recruiting FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas
Conditions: Gastro-enteropancreatic Neuroendocrine Tumor;   Pancreatic Cancer;   Neuroendocrine Carcinomas of Pancreas;   Islet Cell Carcinoma
Interventions: Drug: FOLFIRINOX;   Drug: Granulocyte colony-stimulating factor (G-CSF)
39 Recruiting Cisplatinum and Everolimus in Patients With Metastatic or Unresectable NEC of Extrapulmonary Origin
Condition: Neuroendocrine Carcinomas
Intervention: Drug: cisplatinum and everolimus
40 Recruiting Safety and Tolerability of Everolimus as Second-line Treatment in Poorly Differentiated Neuroendocrine Carcinoma / Neuroendocrine Carcinoma G3 (WHO 2010) and Neuroendocrine Tumor G3 - an Investigator Initiated Phase II Study
Conditions: Poorly Differentiated Malignant Neuroendocrine Carcinoma;   Neuroendocrine Carcinoma, Grade 3;   Neuroendocrine Carcinoma, Grade 1 [Well-differentiated Neuroendocrine Carcinoma] That Switched to G3;   Neuroendocrine Carcinoma, Grade 2 [Moderately Differentiated Neuroendocrine Carcinoma] That Switched to G3;   Neuroendocrine Tumor, Grade 3 and Disease Progression as Measured by Response Evaluation Criteria in Solid Tumors (RECIST 1.1.)
Intervention: Drug: Everolimus (Afinitor®)

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.